Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

BACKGROUND: Until very recently, vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than 16 years of age. Safe, effective vaccines are needed to protect this population, facilitate in-person learning and socializ...

Descripción completa

Detalles Bibliográficos
Autores principales: Frenck, Robert W., Klein, Nicola P., Kitchin, Nicholas, Gurtman, Alejandra, Absalon, Judith, Lockhart, Stephen, Perez, John L., Walter, Emmanuel B., Senders, Shelly, Bailey, Ruth, Swanson, Kena A., Ma, Hua, Xu, Xia, Koury, Kenneth, Kalina, Warren V., Cooper, David, Jennings, Timothy, Brandon, Donald M., Thomas, Stephen J., Türeci, Özlem, Tresnan, Dina B., Mather, Susan, Dormitzer, Philip R., Şahin, Uğur, Jansen, Kathrin U., Gruber, William C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174030/
https://www.ncbi.nlm.nih.gov/pubmed/34043894
http://dx.doi.org/10.1056/NEJMoa2107456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174030/
https://www.ncbi.nlm.nih.gov/pubmed/34043894
http://dx.doi.org/10.1056/NEJMoa2107456

Ejemplares similares